 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Anacor Pharmaceuticals, Inc. (ANAC) focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.
It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails.
The companys lead product candidate includes AN2728, anti-inflammatory product, which is in Phase III clinical trials for the treatment of mild-to-moderate atopic dermatitis and psoriasis.
It is also developing AN2898, an anti-inflammatory product candidate, which has completed Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; AN3365, an antibiotic product candidate for the treatment of infections caused by Gram-negative bacteria; and AN2718, an antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin.
The company has research collaborations with Drugs for Neglected Diseases initiative to develop new therapeutics for human African trypanosomiasis, visceral leishmaniasis, and Chagas disease; research and development collaboration with GlaxoSmithKline LLC for tuberculosis (TB); research, license, and commercialization agreement with Eli Lilly and Company for an animal health indication; and research agreement with The Bill & Melinda Gates Foundation for filarial worm diseases, TB, and cryptosporidiosis.
Shares are heading higher in a bullish "cup & handle" and higher share prices are expected for this stock.
52-Weeks Trading Range: $14.95 - $72.48
Entry Point: $70.00
Stop Loss: $66.50
Target Pirce: $77.00
ANAC closed at $80.60 after it reached our target price
